Compare OBDC & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBDC | SYRE |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.9B |
| IPO Year | 2015 | 2015 |
| Metric | OBDC | SYRE |
|---|---|---|
| Price | $11.82 | $71.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $14.00 | ★ $85.08 |
| AVG Volume (30 Days) | ★ 3.9M | 1.3M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 13.40% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.24 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.52 | $12.29 |
| 52 Week High | $15.19 | $76.00 |
| Indicator | OBDC | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 60.34 | 63.98 |
| Support Level | $11.65 | $30.39 |
| Resistance Level | $12.10 | $74.92 |
| Average True Range (ATR) | 0.28 | 4.18 |
| MACD | 0.05 | -0.71 |
| Stochastic Oscillator | 84.70 | 55.65 |
Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.